Abstract
CHS 828, a cyanoguanidine with potent experimental antitumoural activity, inhibits activation of nuclear factor-kappaB. In the present study, marked antitumoural activity of peroral CHS 828 was shown against three different human neuroendocrine tumours, midgut carcinoid (GOT1), pancreatic carcinoid (BON), and medullary thyroid carcinoma (GOT2), transplanted in nude mice. Our results indicate that CHS 828 can be a candidate drug for treatment of neuroendocrine tumours.
References
Aug 11, 1991·Gastroenterology·B M EversJ C Thompson
Aug 1, 1997·Neurochemical Research·G WestbergB Wängberg
Aug 24, 1999·Molecular and Cellular Biology·C Y WangA S Baldwin
Oct 20, 2000·Oncogene·Q ChengG Cheng
Feb 13, 2001·The American Journal of Pathology·L KölbyO Nilsson
Feb 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P MartinssonR Larsson
Nov 15, 2001·Anti-cancer Drugs·A AleskogE Jonsson
Apr 30, 2002·Pediatric Research·Asa SvenssonRolf Christofferson
May 9, 2002·Biochemical Pharmacology·Henrik LövborgRolf Larsson
Jul 13, 2002·Expert Review of Anticancer Therapy·J A Irving, A G Hall
Jan 7, 2004·Nature Reviews. Drug Discovery·Michael KarinQ May Wang
Jan 10, 2004·International Journal of Radiation Biology·M Abend
Mar 30, 2004·Oncogene·Maria CastedoGuido Kroemer
Apr 13, 2004·Oncogene·Pierluigi Nicotera, Gerry Melino
Apr 20, 2004·Anti-cancer Drugs·Peter HovstadiusRolf Larsson
Jun 16, 2004·International Journal of Cancer. Journal International Du Cancer·Lone Stengelshøj OlsenMogens Winkel Madsen
Mar 15, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alain RavaudChris Twelves
Citations
Sep 2, 2010·Journal of Medicinal Chemistry·Fraser F FlemingBrian C Shook
Oct 31, 2006·Oncogene·T D Gilmore, M Herscovitch
Apr 17, 2009·Anti-cancer Drugs·Pierre BeauparlantMark Watson
May 11, 2012·Neuroendocrinology·Eva Forssell-AronssonHåkan Ahlman
Mar 17, 2009·Journal of Translational Medicine·Dieter FuchsFaranak Azarbayjani
Sep 8, 2015·Biochemical Pharmacology·Nicolas Preyat, Oberdan Leo
Feb 25, 2015·Pharmacology & Therapeutics·Deepak SampathPeter S Dragovich
Nov 15, 2006·Annals of the New York Academy of Sciences·Håkan Ahlman
Jul 6, 2007·BioFactors·Chae Hyeong LeeYong-Sang Song
Mar 30, 2007·Annales d'endocrinologie·D VezzosiP Caron
May 8, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Nadia Sawicka-GutajMarek Ruchała
Jun 15, 2007·Maternal and Child Health Journal·Amira Y El-BastawissiRebecca Manolopoulos
Dec 6, 2019·Oncotarget·Anne-Julie ClouxAimable Nahimana
Oct 1, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Anna-Karin ElfViktor Johanson
Jun 10, 2019·Seminars in Cell & Developmental Biology·Maheshwor Thapa, Guido Dallmann